AIM - AIM ImmunoTech's Ampligen helps improve survival of pancreatic cancer patients in study

AIM ImmunoTech (NYSE:AIM) said Ampligen following FOLFIRINOX, a chemotherapy combination, showed improved survival rates in patients with pancreatic cancer compared to matched controls of patients who did not receive Ampligen. Ampligen (rintatolimod) was evaluated as a monotherapy to treat patients with locally advanced pancreatic cancer (LAPC) or metastatic disease in an Early Access Program (EAP) in the Netherlands at Erasmus Medical Center. The company said the study’s main goals were the Systemic Immune-Inflammation Index (SIII), the Neutrophils to Lymphocyte Ratio (NLR), and absolute counts of 18 different populations of circulating immune cells. Meanwhile, secondary goals were progression-free survival (PFS) and overall survival (OS). Based on OS after Ampligen treatment, 27 patients were divided into 11 long-term survivors and 16 short-term survivors. The company said that at 6 weeks, SIII and the NLR values from the long-term and short-term patients combined showed no significant difference compared to baseline, the values were found to be significantly lower

For further details see:

AIM ImmunoTech's Ampligen helps improve survival of pancreatic cancer patients in study